Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 47n3y | — |
vesicles on her back which was diagnosed as shingles/pustules; This non-serious case was reported by a nurse via call center representative and described the occurrence of shingles in a female patient who received Herpes zoster (Shingrix) (batch number 47n3y, expiry date 30-MAR-2027) for prophylaxis. On 16-APR-2025, the patient received the 1st dose of Shingrix. In APR-2025, 3 days after receiving Shingrix, the patient experienced shingles (Verbatim: vesicles on her back which was diagnosed as shingles/pustules). The outcome of the shingles was unknown. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 28-APR-2025 The reporter stated that a patient received her first dose of Shingrix and 3 days later, she came back with vesicles on her back which was diagnosed as shingles. Also stated that there were 10 little pustules with the area with the diameter of about 2 in in the left upper quadrant on the patient's back below the left scapula. This case is linked with case US2025051115, reported by the same reporter.; Sender's Comments: US-GSK-US2025051115:SAME REPORTER